Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events

Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported...

Descripción completa

Detalles Bibliográficos
Autores: Alserawan, Leticia|||0000-0003-0428-9844, Anguera, Georgia|||0000-0002-6060-1110, Zamora, Carlos|||0000-0003-2962-678X, Serra, Jorgina|||0000-0002-2363-7149, Martinez-Martinez, Laura|||0000-0003-0126-158X, Riudavets Melià, M., Sullivan, Ivana|||0000-0002-0434-3436, Barba Joaquin, Andrés|||0000-0003-2500-0253, Majem Tarruella, Margarita|||0000-0002-9919-7485, Vidal, Silvia|||0000-0002-3909-6682
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:275158
Acceso en línea:https://ddd.uab.cat/record/275158
https://dx.doi.org/urn:doi:10.3390/ijms232012641
Access Level:acceso abierto
Palabra clave:Immune-related adverse events (irAEs)
Anti-PD-(L)1 blocking agents
Antinuclear autoantibodies (ANA)
Predictive biomarkers
Immune checkpoint inhibitors
id ES_e95b9ddaf6efbdf6c9c4aeecf3744e81
oai_identifier_str oai:ddd.uab.cat:275158
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse EventsAlserawan, Leticia|||0000-0003-0428-9844Anguera, Georgia|||0000-0002-6060-1110Zamora, Carlos|||0000-0003-2962-678XSerra, Jorgina|||0000-0002-2363-7149Martinez-Martinez, Laura|||0000-0003-0126-158XRiudavets Melià, M.Sullivan, Ivana|||0000-0002-0434-3436Barba Joaquin, Andrés|||0000-0003-2500-0253Majem Tarruella, Margarita|||0000-0002-9919-7485Vidal, Silvia|||0000-0002-3909-6682Immune-related adverse events (irAEs)Anti-PD-(L)1 blocking agentsAntinuclear autoantibodies (ANA)Predictive biomarkersImmune checkpoint inhibitorsImmune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. Our goal was to compare ANA patterns by indirect immunofluorescence at different timepoints before (baseline) and after the initiation of ICI treatment and to analyze the role of ANA pattern changes as predictors of irAEs. This is a 2-year-follow-up prospective study of 152 consecutive patients with solid tumors treated with anti-PD-(L)1 blockade agents. They were included from September 2018 until March 2020 in the Hospital de la Santa Creu I Sant Pau (Barcelona, Spain). We grouped patients into three groups: ANA de novo (patients who showed new ANA patterns at any time after ICI initiation), ANA (ANA positive at baseline without changes in the ANA patterns after initiation of treatment) and non-ANA (ANA negative at baseline and after ICI initiation). We did not find any association between the appearance of ANAs and irAE rates or the number and types of irAEs. However, patients in the ANA de novo group showed higher severe irAE rates (grade ≥ 3) than the other groups. Additionally, in most of the patients with severe irAEs (83.3%), changes in ANA patterns preceded irAE onset. In conclusion, we found ANA induction during ICI therapies in 22 patients and our results suggest that the appearance of ANAs may predict the severity of the irAE. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/275158https://dx.doi.org/urn:doi:10.3390/ijms232012641reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2751582026-06-06T12:50:31Z
dc.title.none.fl_str_mv Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
spellingShingle Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
Alserawan, Leticia|||0000-0003-0428-9844
Immune-related adverse events (irAEs)
Anti-PD-(L)1 blocking agents
Antinuclear autoantibodies (ANA)
Predictive biomarkers
Immune checkpoint inhibitors
title_short Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_full Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_fullStr Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_full_unstemmed Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_sort Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
dc.creator.none.fl_str_mv Alserawan, Leticia|||0000-0003-0428-9844
Anguera, Georgia|||0000-0002-6060-1110
Zamora, Carlos|||0000-0003-2962-678X
Serra, Jorgina|||0000-0002-2363-7149
Martinez-Martinez, Laura|||0000-0003-0126-158X
Riudavets Melià, M.
Sullivan, Ivana|||0000-0002-0434-3436
Barba Joaquin, Andrés|||0000-0003-2500-0253
Majem Tarruella, Margarita|||0000-0002-9919-7485
Vidal, Silvia|||0000-0002-3909-6682
author Alserawan, Leticia|||0000-0003-0428-9844
author_facet Alserawan, Leticia|||0000-0003-0428-9844
Anguera, Georgia|||0000-0002-6060-1110
Zamora, Carlos|||0000-0003-2962-678X
Serra, Jorgina|||0000-0002-2363-7149
Martinez-Martinez, Laura|||0000-0003-0126-158X
Riudavets Melià, M.
Sullivan, Ivana|||0000-0002-0434-3436
Barba Joaquin, Andrés|||0000-0003-2500-0253
Majem Tarruella, Margarita|||0000-0002-9919-7485
Vidal, Silvia|||0000-0002-3909-6682
author_role author
author2 Anguera, Georgia|||0000-0002-6060-1110
Zamora, Carlos|||0000-0003-2962-678X
Serra, Jorgina|||0000-0002-2363-7149
Martinez-Martinez, Laura|||0000-0003-0126-158X
Riudavets Melià, M.
Sullivan, Ivana|||0000-0002-0434-3436
Barba Joaquin, Andrés|||0000-0003-2500-0253
Majem Tarruella, Margarita|||0000-0002-9919-7485
Vidal, Silvia|||0000-0002-3909-6682
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Immune-related adverse events (irAEs)
Anti-PD-(L)1 blocking agents
Antinuclear autoantibodies (ANA)
Predictive biomarkers
Immune checkpoint inhibitors
topic Immune-related adverse events (irAEs)
Anti-PD-(L)1 blocking agents
Antinuclear autoantibodies (ANA)
Predictive biomarkers
Immune checkpoint inhibitors
description Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. Our goal was to compare ANA patterns by indirect immunofluorescence at different timepoints before (baseline) and after the initiation of ICI treatment and to analyze the role of ANA pattern changes as predictors of irAEs. This is a 2-year-follow-up prospective study of 152 consecutive patients with solid tumors treated with anti-PD-(L)1 blockade agents. They were included from September 2018 until March 2020 in the Hospital de la Santa Creu I Sant Pau (Barcelona, Spain). We grouped patients into three groups: ANA de novo (patients who showed new ANA patterns at any time after ICI initiation), ANA (ANA positive at baseline without changes in the ANA patterns after initiation of treatment) and non-ANA (ANA negative at baseline and after ICI initiation). We did not find any association between the appearance of ANAs and irAE rates or the number and types of irAEs. However, patients in the ANA de novo group showed higher severe irAE rates (grade ≥ 3) than the other groups. Additionally, in most of the patients with severe irAEs (83.3%), changes in ANA patterns preceded irAE onset. In conclusion, we found ANA induction during ICI therapies in 22 patients and our results suggest that the appearance of ANAs may predict the severity of the irAE.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/275158
https://dx.doi.org/urn:doi:10.3390/ijms232012641
url https://ddd.uab.cat/record/275158
https://dx.doi.org/urn:doi:10.3390/ijms232012641
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423020348538880
score 15,300719

Similares en LA Referencia